Categories: NewsPharmaceutical

Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.

Webcast
The webcasted fireside chat will take place at 1:15pm ET on Thursday, May 30, 2024. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2024/ or directly at https://wsw.com/webcast/lytham11/aytu/2126355. The webcast will also be available for replay following the event.

1×1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/spring2024invreg/.

About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.

Contacts for Investors:
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com

Robert Blum or Roger Weiss
Lytham Partners
AYTU@lythampartners.com

SOURCE: Aytu BioPharma, Inc.

View the original press release on accesswire.com

Staff

Recent Posts

Humana Redefines the Member Experience with Agent Assist Built with Google Cloud

Humana introduces Agent Assist to help member advocates deliver faster, more personalized support, enabled by…

6 hours ago

AssureCare Announces Parth Shah’s Promotion to Senior Vice President of Customer Success and Enterprise AI Delivery

CINCINNATI, Feb. 3, 2026 /PRNewswire/ -- AssureCare® LLC, a leading healthcare technology company delivering an…

6 hours ago

Doxim Scales Utility Payments Team to Support Rapid Market Growth

Doxim's Utility Payments Team will drive seamless, omnichannel billing-to-payments solutions for utilities to bridge the…

6 hours ago

Amplifire Recognized by Brandon Hall Group for Breakthrough AI Authoring Technology

BOULDER, Colo., Feb. 3, 2026 /PRNewswire/ -- Amplifire, the leading adaptive learning platform built on patented…

6 hours ago

Cognision Launches Cognision360™: A Unified Platform Transforming Neurobiomarker Acquisition, Processing, and Analysis in CNS Clinical Trials

LOUISVILLE, Ky., Feb. 3, 2026 /PRNewswire/ -- Cognision today unveiled Cognision360™, a groundbreaking web-based platform that consolidates…

6 hours ago